- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00073866
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase I/II Trial Of Weekly Irinotecan And Docetaxel With The Addition Of Celecoxib In Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Combining celecoxib with combination chemotherapy may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan and docetaxel when given together with celecoxib and to see how well they work in treating patients with advanced non-small cell lung cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Determine the recommended phase II dose of docetaxel and irinotecan in combination with celecoxib in patients with advanced non-small cell lung cancer.
- Determine the toxic effects of this regimen in these patients.
- Determine the response rate of patients treated with this regimen.
- Determine the progression-free and overall survival of patients treated with this regimen.
- Determine the pharmacokinetics of this regimen in these patients.
- Correlate angiogenesis markers (intratumoral microvessel density and vascular endothelial growth factor [VEGF] expression and serum VEGF) and cyclooxygenase-2 expression with response and survival in patients treated with this regimen.
- Correlate UGT1A1 genotype and CYP3A4 activity with the toxic effects of this regimen in these patients.
OUTLINE: This is a dose-escalation study of docetaxel and irinotecan.
- Phase I: Patients receive docetaxel IV over 60 minutes and irinotecan IV over 30 minutes on days 1 and 8. Patients also receive oral celecoxib twice daily beginning on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity Cohorts of 3-6 patients receive escalating doses of docetaxel and irinotecan until the recommended phase II dose is determined. The recommended phase II dose is defined as the highest dose at which 0 of 3 or 1 of 6 patients experience dose-limiting toxicity.
- Phase II: Patients receive treatment as in phase I at the recommended phase II dose.
Patients are followed every 3 months until disease progression.
PROJECTED ACCRUAL: A total of 3-70 patients (3-36 for phase I and 16-34 for phase II) will be accrued for this study.
Tipo de estudio
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611-3013
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
Evanston, Illinois, Estados Unidos, 60201
- Evanston Northwestern Health Care - Evanston Hospital
-
Joliet, Illinois, Estados Unidos, 60432
- Silver Cross Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Diagnosis of non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:
- Stage IV
- Stage IIIB with a malignant pleural effusion
- Locally recurrent and/or persistent disease after locoregional therapy with or without systemic chemotherapy
Unidimensionally measurable disease
- If the only site of measurable disease is in a previously irradiated area must have documented progression of disease in that area
- No CNS metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin normal
- AST and ALT less than 2.5 times upper limit of normal (ULN) (if alkaline phosphatase is normal)
- Alkaline phosphatase less than 4 times ULN (if AST and ALT are normal)
Renal
- Creatinine less than 2.0 mg/dL
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study treatment
- No other malignancy within the past 5 years except curatively treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
- No diagnosis of peptic ulcer disease or gastritis/esophagitis within the past 60 days
- No prior hypersensitivity to cyclooxygenase-2 (COX-2) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, sulfonamides, or drugs formulated with polysorbate 80
- No pre-existing grade 2 or greater peripheral neuropathy
- No concurrent medical condition that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- At least 1 week since prior biologic therapy
Phase I patients:
- Any number of prior biologic therapies allowed (e.g., chimeric antibodies or kinase inhibitors)
Phase II patients:
- No prior biologic therapy for recurrent/metastatic disease
- No concurrent filgrastim (G-CSF)
Chemotherapy
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- No prior irinotecan or docetaxel
Phase I patients:
- Up to 2 prior chemotherapy regimens for recurrent/metastatic disease allowed (chemonaïve patients are also eligible)
Phase II patients:
- At least 1 year since prior adjuvant or neoadjuvant chemotherapy for stage I-IIIA disease
- No prior chemotherapy for recurrent/metastatic disease
Endocrine therapy
- Less than 2 weeks of cumulative oral/IV corticosteroid use within the past 3 months
Radiotherapy
- See Disease Characteristics
- Recovered from prior radiotherapy
- At least 3 weeks since prior extensive-field radiotherapy for recurrent/metastatic disease
Surgery
- Recovered from prior surgery
Other
- More than 60 days since prior treatment for peptic ulcer disease or gastritis/esophagitis
- No prior NSAIDs at a frequency of more than 3 times per week for a cumulative period of more than 2 weeks within the past 30 days
- No concurrent antiepileptics, cyclosporine, aspirin, or fluconazole
- No concurrent NSAIDs
- No other concurrent COX-2 inhibitors
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Athanassios Argiris, MD, Robert H. Lurie Cancer Center
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes del sistema nervioso periférico
- Inhibidores de enzimas
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Inhibidores de la ciclooxigenasa
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Inhibidores de la topoisomerasa
- Inhibidores de la ciclooxigenasa 2
- Inhibidores de la topoisomerasa I
- Docetaxel
- Celecoxib
- Irinotecán
Otros números de identificación del estudio
- NU 01L2
- NU-01L2
- PHARMACIA-NU-01L2
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de pulmón
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre docetaxel
-
Nereus Pharmaceuticals, Inc.TerminadoCáncerEstados Unidos, Australia, India, Chile, Brasil, Argentina
-
Optimal Health ResearchTerminadoCáncer de mama | Cáncer de pulmón | Cancer de prostataEstados Unidos
-
Tianjin Medical University Cancer Institute and...Reclutamiento
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaTerminadoCáncer de pulmón de células no pequeñas (CPCNP)Porcelana
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center y otros colaboradoresDesconocidoCáncer gástricoCorea, república de
-
Zhuhai Beihai Biotech Co., LtdTerminadoTumores Sólidos | Bioequivalencia | DocetaxelIndia
-
Arog Pharmaceuticals, Inc.RetiradoCarcinoma de pulmón de células no pequeñas
-
SanofiTerminadoNeoplasias PulmonaresFrancia, Países Bajos, España, Pavo, Bélgica, Finlandia, Italia, Reino Unido
-
SanofiTerminadoNeoplasias de Cabeza y CuelloFrancia
-
Fudan UniversityAún no reclutandoCáncer de pulmón de células no pequeñas avanzado